Tag: Boehringer Ingelheim
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates ... Read More
Boehringer Ingelheim expands pets vaccines production facility in Athens
German pharma giant Boehringer Ingelheim has wrapped up the $76 million expansion of its pets vaccines production facility at Athens in Georgia, US. The investment ... Read More
Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as ... Read More
Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics
German pharma company Boehringer Ingelheim has exercised its option to acquire 100% of Austria-based oncolytic virus company ViraTherapeutics for €210 million in a move to ... Read More
Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial
German pharma company Boehringer Ingelheim said that Cyltezo, a biosimilar to AbbVie psoriasis drug Humira, achieved clinical equivalence to the reference product in a phase ... Read More